Problems of early diagnosis of hereditary neurological diseases
https://doi.org/10.21508/1027-4065-2021-66-4-8-15
Abstract
Hereditary neurological diseases represent a substantial part of human monogenic disorders. Most of them are progressive, disabling,and lacking disease-modifying therapy. Early diagnosis of severe genetic neurological conditions is essentialfor primaryand secondary prevention, genetic counseling and family planning. Modern methods of prenatal and preimplantation DNA diagnostics significantly reduce the likelihood of havinga sickchild. At the same time, neonatal and selective screening of newborns and young children makes it possible to diagnose hereditary neurological diseases as early as possible and to start pathogenetic therapy, which is currently available for a number of pathologies. The widespreadintroduction of biochemical and molecular diagnostics of the hereditary neurological diseases in patients of various ages, including modern methods of massive parallel sequencing, gives rise to technological, ethical and financial problems.
About the Authors
S. N. Illarioshkin
Research Center of Neurology
Russian Federation
Russian Federation
Moscow
Yu. A. Seliverstov
Research Center of Neurology
Russian Federation
Russian Federation
Moscow
S. A. Klyushnikov
Research Center of Neurology
Russian Federation
Russian Federation
Moscow
References
1. Jackson M., Marks L., May G.H., Wilson J.B. The genetic basis of the disease. Essays Biochem 2018; 62(5): 643–723. DOI: 10.1042/EBC20170053
2. Borodinov A.G., Manoilov V.V., Zarutski I.V., Petrov А.I., Kurochkin V.E. Generations of DNA sequencing techniques. Nauchnoe priborostroenie 2020; 30(4): 3–20. DOI: 10.18358/np-30-4-i320 (in Russ.)
3. Ilyas M. Next-generation sequencing in diagnostic pathology. Pathobiol 2017; 84(6): 292–305. DOI: 10.1159/000480089
4. Feigin V.L., Vos T., Nichols E., Owolabi M.O., Carroll W.M., Dichgans M. et al. The global burden of neurological disorders: translating evidence into policy. Lancet Neurol 2020; 19(3): 255–265. DOI: 10.1016/S1474-4422(19)30411-9
5. Sullivan-Pyke C., Dokras A. Preimplantation genetic screening and preimplantation genetic diagnosis. Obstet Gynecol Clin North Am 2018; 45(1): 113–125. DOI: 10.1016/j.ogc.2017.10.009
6. Baidakova G.V., Zakharova E.Yu., Kani vets I.V., Konovalov F.A., StrelnikovV.V., Kutsev S.I. Diagnosis of congenital and hereditary diseases in children: achievements and development prospects. Vestnik Roszdravnadzora 2016; 3:27–33. (In Russ.)
7. Mohammad S.S., Paget S.P., Dale R.C. Current therapies and therapeutic decision making for childhood-onset movement disorders. Mov Disord 2019; 34: 637–656. DOI: 10.1002/mds.27661
8. Ebrahimi-Fakhari D., Van Karnebeek C., Münchau A. Movement disorders in treatable inborn errors of metabolism. Mov Disord 2019; 34: 598–613. DOI: 10.1002/mds.27568
9. Marques Matos C., Alonso I., Leão M. Diagnostic yield of next-generation sequencing applied to neurological disorders. J Clin Neurosci 2019; 67: 14–18. DOI: 10.1016/j.jocn.2019.06.041
10. Thompson R., Spendiff S., Roos A., Bourque P.R., Warman Chardon J., Kirschner J. et al. Advances in the diagnosis of inherited neuromuscular diseases and implications for therapy development. Lancet Neurol 2020; 19: 522–532. DOI: 10.1016/S1474-4422(20)30028-4
11. Illarioshkin S.N., Shadrina M.I., Slominsky P.A., Bespalova E.V., Zagorovskaya T.B., Bagyeva G.Kh. et al. A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson’s disease in Russia. Eur J Neurol 2007; 14(4): 413–417. DOI: 10.1111/j.1468-1331.2007.01685.x
12. Platonov F.A., Illarioshkin S.N., KononovaS.K.,GogolevM.P.,Ivanova-SmolenskaiaI.A. Spinocerebellar ataxia type 1 in Yakutia: prevalence and clinical and genetic comparisons. Meditsinskaya genetika 2004; 5: 242–248. (in Russ.)
13. Chien Y.H., Lee N.C., Hwu W.L., Fang J.Y. Disease progression in a pre-symptomatically treated patient with juvenile-onset Pompe disease – need for an earlier treatment? Eur J Neurol 2018; 25(10): e111. DOI: 10.1111/ene.13730
14. Di Rocco M., Dardis A., Madeo A., Barone R., Fiumara A. Early miglustat therapy in infantile Niemann-Pick disease type C. Pediatr Neurol 2012; 47(1): 40–43. DOI: 10.1016/j.pediatrneurol.2012.04.005
15. Klyushnikov S.A., Ivanova-Smolenskaia I.A., Nikolskaja N.N., Illarioshkin S.N., Markova E.D., Bodareva E.A. Ethical issues of medical genetic counseling on the example of Huntington’s chorea. Rossiiskii meditsinskii zhurnal 2000; 2: 32–36. (in Russ.)
16. Cozaru G.C., Aşchie M., Mitroi A.F., Poinăreanu I., Gorduza E.V. Ethical and genetic aspects regarding presymptomatic testing for neurodegenerative diseases. Rev Med Chir Soc Med Nat Iasi 2016; 120 (1): 15-22
17. Illarioshkin S.N., Klyushnikov S.A., Selivyorstov Yu.A. Huntington’s disease. Moscow: ATMO, 2018; 472. (in Russ.)
18. Nikolaeva E.A., Semyachkina A.N. Modern possibilities of treating hereditary diseases in children. Rossiyskiy vestnik perinatologii i pediatrii 2018; 63(4): 6–14. DOI: 10.21508/1027-4065-2018-63-4-6-14 (in Russ.)
Review
For citations:
Illarioshkin S.N., Seliverstov Yu.A., Klyushnikov S.A. Problems of early diagnosis of hereditary neurological diseases. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2021;66(4):8-15. (In Russ.) https://doi.org/10.21508/1027-4065-2021-66-4-8-15
Views:
1218
Email this article 